Thymosin Alpha-1
Peptides

Thymosin Alpha-1

Thymosin Alpha-1 (Ta1)

A powerful immune-modulating peptide naturally produced by the thymus gland. FDA orphan drug status for hepatitis B and approved in 35+ countries. Used for chronic infections, cancer immunotherapy support, immune aging, and long COVID recovery.

80+ Studies70+ ReportsStrongInjectableAvailable in UAE
80
Kamura ScoreStrong
80/100
Strong
Strong
Evidence
2-4 weeks
Time to Effect
AED 500-1500/month
Est. Cost
Available
UAE Access
Last reviewed: March 2025
82
Research
80
Community
85
Safety
60
Access
68
Value

How Thymosin Alpha-1 Works

Thymosin Alpha-1 activates toll-like receptors on dendritic cells, promotes T-cell differentiation and maturation in the thymus, enhances NK cell cytotoxicity, and modulates cytokine balance toward an anti-tumor, anti-viral immune response.

📊 Evidence by Outcome

Immune System EnhancementA

Stimulates T-cell maturation, NK cell activity, and dendritic cell function. One of the most comprehensively studied immune peptides.

30 studies • Consistency: High • Effect: Large

Cancer Immunotherapy SupportB

Improved survival when combined with chemotherapy in hepatocellular carcinoma and melanoma. Enhances checkpoint inhibitor response.

15 studies • Consistency: Moderate • Effect: Moderate

Chronic Infection ResolutionB

Clinical efficacy in chronic hepatitis B and C. Used for chronic Lyme, EBV reactivation, and long COVID immune dysregulation.

20 studies • Consistency: Moderate • Effect: Moderate

📄

Key Research

Peer-Reviewed Evidence • 1 Citations

[1]

Thymosin alpha 1 in the treatment of cancer: a systematic review

Maio M et al.Cancer Treatment Reviews2020

Key Finding: Systematic review confirmed improved immune biomarkers and survival benefits when Ta1 is combined with chemotherapy or immunotherapy across multiple cancer types.

Citations sourced from PubMed, Cochrane Library, and peer-reviewed journals. Study findings are summarized for accessibility. Always consult the original publication for full methodology and results.

📋 Protocol Snapshot

Immune Support
1.6mg SubQ, 2-3x/week
Standard immune modulation dose. Inject subcutaneously. Cycle 8-12 weeks on, then reassess.
Acute Immune Challenge
1.6mg SubQ daily x 7-14 days
Short-term intensive protocol for acute infections or immune crisis.

Protocols are for informational purposes only. Always consult a qualified healthcare provider before starting any treatment protocol.

Cost Guide

AED 500-1500/month

Estimated UAE pricing. Costs vary by provider, dosage, and treatment plan.

Where to Get It (UAE)

Browse all wellness centers →

Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice. Kamura Scores reflect a combination of research evidence, community data, and other factors — they are not clinical recommendations. Research citations are provided for reference; always consult the original publications for complete study details. Consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Individual results may vary.